Daniel Cain is an experienced professional in the pharmaceutical industry with a focus on rare diseases and acute care settings. Currently serving as an Executive Therapeutic Specialist and Field Based Trainer at Insmed Incorporated since February 2018, Daniel played a crucial role in the launch of Arikayce, the first treatment for MAC lung disease. Prior experience includes a position as a Senior Therapeutic Specialist and Regional Trainer at Gilead Sciences, where Daniel ranked among the top nationally for performance. Additional roles at Johnson & Johnson involved launching Xarelto in acute care hospitals, while earlier tenure at sanofi-aventis included managing institutional sales in cardiology. Daniel holds a BS in Business Logistics and an MBA from Penn State University.
This person is not in any teams
This person is not in any offices